Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Equity to Asset 0.32
BIOS's Equity to Asset is ranked higher than
62% of the 307 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. BIOS: 0.32 )
BIOS' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.75
Current: 0.32

0.27
0.75
F-Score: 3
Z-Score: 1.10
M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4.42
BIOS's Operating margin (%) is ranked higher than
54% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 8.52 vs. BIOS: -4.42 )
BIOS' s 10-Year Operating margin (%) Range
Min: -11.69   Max: 4.61
Current: -4.42

-11.69
4.61
Net-margin (%) -9.95
BIOS's Net-margin (%) is ranked higher than
54% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 4.94 vs. BIOS: -9.95 )
BIOS' s 10-Year Net-margin (%) Range
Min: -16.05   Max: 9.77
Current: -9.95

-16.05
9.77
ROE (%) -31.01
BIOS's ROE (%) is ranked higher than
51% of the 289 Companies
in the Global Medical Care industry.

( Industry Median: 10.03 vs. BIOS: -31.01 )
BIOS' s 10-Year ROE (%) Range
Min: -57.57   Max: 43.05
Current: -31.01

-57.57
43.05
ROA (%) -11.36
BIOS's ROA (%) is ranked higher than
51% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 3.52 vs. BIOS: -11.36 )
BIOS' s 10-Year ROA (%) Range
Min: -27.23   Max: 20.26
Current: -11.36

-27.23
20.26
ROC (Joel Greenblatt) (%) -29.93
BIOS's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 309 Companies
in the Global Medical Care industry.

( Industry Median: 18.24 vs. BIOS: -29.93 )
BIOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -902.86   Max: 227.09
Current: -29.93

-902.86
227.09
Revenue Growth (3Y)(%) 15.10
BIOS's Revenue Growth (3Y)(%) is ranked higher than
90% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. BIOS: 15.10 )
BIOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -35   Max: 15.9
Current: 15.1

-35
15.9
EPS Growth (3Y)(%) -14.80
BIOS's EPS Growth (3Y)(%) is ranked higher than
61% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 13.80 vs. BIOS: -14.80 )
BIOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -82.7   Max: 40.2
Current: -14.8

-82.7
40.2
» BIOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BIOS Guru Trades in Q4 2013

Ron Baron 37,530 sh (New)
Kyle Bass 400,000 sh (New)
Pioneer Investments 280,320 sh (New)
Mario Gabelli 57,400 sh (+132.39%)
Alan Fournier 5,096,473 sh (+43.81%)
Louis Moore Bacon Sold Out
Paul Tudor Jones 12,500 sh (-60.06%)
Steven Cohen 5,700 sh (-67.19%)
» More
Q1 2014

BIOS Guru Trades in Q1 2014

Steven Cohen 1,400,200 sh (+24464.9%)
Mario Gabelli 818,775 sh (+1326.44%)
Ron Baron 144,010 sh (+283.72%)
Pioneer Investments 280,320 sh (unchged)
Alan Fournier Sold Out
Kyle Bass Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2014

BIOS Guru Trades in Q2 2014

Mario Gabelli 1,440,840 sh (+75.98%)
Steven Cohen 416,500 sh (unchged)
Pioneer Investments 280,320 sh (unchged)
Ron Baron 144,010 sh (unchged)
» More
Q3 2014

BIOS Guru Trades in Q3 2014

Ron Baron 281,300 sh (+95.33%)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 1,431,426 sh (-0.65%)
Steven Cohen 92,100 sh (-77.89%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-09-30 Add 95.33%$6.85 - $8.55 $ 6.12-21%281300
Mario Gabelli 2014-06-30 Add 75.98%0.03%$6.09 - $8.35 $ 6.12-18%1440840
Mario Gabelli 2014-03-31 Add 1326.44%0.03%$6.75 - $8.69 $ 6.12-21%818775
Ron Baron 2014-03-31 Add 283.72%$6.75 - $8.69 $ 6.12-21%144010
Ron Baron 2013-12-31 New Buy$5.65 - $8.58 $ 6.12-13%37530
Mario Gabelli 2013-12-31 Add 132.39%$5.65 - $8.58 $ 6.12-13%57400
Wilbur Ross 2012-12-31 Sold Out 0.03%$8.85 - $10.92 $ 6.12-38%0
Mario Gabelli 2012-12-31 Add 40.71%$8.85 - $10.92 $ 6.12-38%19700
Wilbur Ross 2012-09-30 Reduce -86.94%0.18%$6.32 - $9.11 $ 6.12-20%39456
Mario Gabelli 2012-09-30 New Buy$6.32 - $9.11 $ 6.12-20%14000
Joel Greenblatt 2012-06-30 Sold Out 0.12%$6.52 - $7.85 $ 6.12-14%0
Joel Greenblatt 2012-03-31 Add 187.1%0.08%$5.22 - $6.97 $ 6.127%200607
Wilbur Ross 2012-03-31 Reduce -25.51%0.04%$5.22 - $6.97 $ 6.127%331156
Joel Greenblatt 2011-12-31 New Buy0.05%$5.14 - $6.99 $ 6.122%69873
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on BioScrip Inc

Baron Funds Comments on BioScrip Inc. - Feb 26, 2014

BioScrip, Inc. (BIOS), an operator of infusion therapy pharmacies, fell 16.5% for the Fund in the quarter. While the company continues to execute its strategy of consolidating the infusion services industry, it stumbled after a non-core legacy business performed worse than expected. While the miscue is not dire for the company, it hurt management's credibility after it had to reset guidance. We continue to believe there is substantial value and growth in the core infusion business, and that this has been validated by CVS's purchase in December of the number two player in the space, Coram, for a very high multiple of cash flow.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Top Ranked Articles about BioScrip Inc

Mario Gabelli Boosts BioScrip Inc. Position
Mario Gabelli (Trades, Portfolio), the founder of the $49.4 billion asset management firm GAMCO Investors (GBL), has increased his stake in BioScrip Inc. (BIOS), according to GuruFocus Real Time Picks. Gabelli holds 3,636,600 shares, or 5.3% of the company, after the 40.2% position increase. Read more...
Gurus' Real Time Stock Picks of the Week
The following information is a highlight of the real-time guru activity we saw this week. To view more information on these gurus, check out their guru portfolios. The “Real Time Picks” reports the stock purchases and sells that Gurus have made within the prior two weeks. If a Guru makes a purchase or sell of a company in which they own a greater-than 5% stake, SEC regulations require them to report their transaction within two days. This week we saw notable increases and buys in Real Time activity from Mario Gabelli (Trades, Portfolio) and Robert Karr (Trades, Portfolio). Read more...
Baron Funds Comments on BioScrip Inc.
BioScrip, Inc. (BIOS), an operator of infusion therapy pharmacies, fell 16.5% for the Fund in the quarter. While the company continues to execute its strategy of consolidating the infusion services industry, it stumbled after a non-core legacy business performed worse than expected. While the miscue is not dire for the company, it hurt management's credibility after it had to reset guidance. We continue to believe there is substantial value and growth in the core infusion business, and that this has been validated by CVS's purchase in December of the number two player in the space, Coram, for a very high multiple of cash flow. Read more...

Ratios

vs
industry
vs
history
P/B 1.50
BIOS's P/B is ranked higher than
89% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 2.93 vs. BIOS: 1.50 )
BIOS' s 10-Year P/B Range
Min: 0.3   Max: 3.1
Current: 1.5

0.3
3.1
P/S 0.40
BIOS's P/S is ranked higher than
92% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. BIOS: 0.40 )
BIOS' s 10-Year P/S Range
Min: 0.04   Max: 1.89
Current: 0.4

0.04
1.89
EV-to-EBIT -18.48
BIOS's EV-to-EBIT is ranked higher than
58% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 24.30 vs. BIOS: -18.48 )
BIOS' s 10-Year EV-to-EBIT Range
Min: -509.1   Max: 1645.4
Current: -18.48

-509.1
1645.4
Current Ratio 1.59
BIOS's Current Ratio is ranked higher than
80% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. BIOS: 1.59 )
BIOS' s 10-Year Current Ratio Range
Min: 0.86   Max: 2.76
Current: 1.59

0.86
2.76
Quick Ratio 1.34
BIOS's Quick Ratio is ranked higher than
77% of the 310 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. BIOS: 1.34 )
BIOS' s 10-Year Quick Ratio Range
Min: 0.79   Max: 2.5
Current: 1.34

0.79
2.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 5.70
BIOS's Price/DCF (Projected) is ranked higher than
73% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 4.02 vs. BIOS: 5.70 )
BIOS' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 12.03
Current: 5.7

0.57
12.03
Price/Median PS Value 1.60
BIOS's Price/Median PS Value is ranked higher than
63% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. BIOS: 1.60 )
BIOS' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.48
Current: 1.6

0.21
5.48
Earnings Yield (Greenblatt) -5.40
BIOS's Earnings Yield (Greenblatt) is ranked higher than
52% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 4.60 vs. BIOS: -5.40 )
BIOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.4   Max: 10.6
Current: -5.4

-5.4
10.6
Forward Rate of Return (Yacktman) -88.89
BIOS's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 12.92 vs. BIOS: -88.89 )
BIOS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -88.6   Max: 54.5
Current: -88.89

-88.6
54.5

Business Description

Industry: Health Care Providers » Medical Care
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:MM6.Germany,
BioScrip Inc, formerly known as MIM Corporation, was incorporated in Delaware in 1996. The Company provides home infusion and other home healthcare services to patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivers cost-effective access to prescription medications and home health services. Its services are provided in coordination with, and under the direction of the patient's physicians. The Company operates in three reportable segments: Infusion Services, Home Health Services, and Pharmacy Benefit Management Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment products and services. Infusion Services include the dispensing and administering of infusion-based drugs, which requires additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home Health Services provides services that include the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home. The integrated Pharmacy Benefit Management Services' operating and reportable segment consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. The discount card allows an individual to receive prescription medications at a discounted price compared to the retail price. The Company has approximately 250 sales and marketing representatives and over 1,000 payor relationships including MCOs, Medicare Part D pharmacy networks, other government programs such as Medicare and Medicaid and other Third Party Payors. The sales and marketing efforts are focused on payors, healthcare systems and physician prescribers and are driven by dedicated managed care and physician sales teams as well as home health care consultants. PBM Services has over 100 relationships with PBM clients, including Medicaid MCOs, employers, TPAs, workers compensation providers and discount card marketers. The Company undertakes direct sales methods to promote the discount card program and add new marketing organizations. The Company owns trademarks, trade names and service marks including BioScrip, BioScrip Infusion Services, BioScrip Medical Supply Services, BioScrip PBM Services, BioScrip Pharmacy Services, Applied Health Care, CarePoint Partners, Critical Homecare Solutions, Deaconess HomeCare, Deaconess Hospice, among others. The Company's competitors within the home infusion market include Walgreen Co., including OptionCare and Critical Care Systems; CVS Caremark Corp., through its recent acquisition of the Coram infusio
» More Articles for NAS:BIOS

Headlines

Articles On GuruFocus.com
Mario Gabelli Boosts BioScrip Inc. Position Oct 28 2014 
Soros and Gabelli Top Guru Real Time Picks of the Week Aug 08 2014 
Gurus' Real Time Stock Picks of the Week May 09 2014 
Morning Coffee: Real-Time Picks May 07 2014 
Morning Coffee: Real-Time Guru Picks Apr 02 2014 
Baron Funds Comments on BioScrip Inc. Feb 26 2014 
BIOS, INWK, LAYN - Mario Gabelli Update Nov 08 2013 
BioScrip Inc. Reports Operating Results (10-Q) Nov 03 2010 
BioScrip Inc. (BIOS) President and COO Richard M Smith buys 10,000 Shares Aug 09 2010 
Weekly CFO Buys Highlight: Riverview Bancorp, BioScrip, Cascade Financial, Bank Mutual, Sykes Enterp Aug 07 2010 

More From Other Websites
From One Woman Board Member in Emerging Markets to 1,500 Dec 17 2014
BioScrip Supports the Toys for Tots Fund Drive and Collection for Second Year Dec 10 2014
BioScrip to Present at Bank of America Merrill Lynch 2014 Leveraged Finance Conference Nov 26 2014
BioScrip to Present at Bank of America Merrill Lynch 2014 Leveraged Finance Conference Nov 26 2014
UPDATE: Barrington Research Initiates Coverage On BioScrip On Positive Outlook Nov 20 2014
BIOSCRIP, INC. Financials Nov 15 2014
10-Q for BioScrip, Inc. Nov 09 2014
BIOSCRIP, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2014
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top Nov 07 2014
BioScrip (BIOS) Stock Lower Today After Third Quarter Earnings Results Nov 06 2014
BioScrip Inc Earnings Call scheduled for 8:30 am ET today Nov 06 2014
BioScrip reports 3Q loss Nov 06 2014
BioScrip reports 3Q loss Nov 06 2014
BioScrip Closes Private Placement of $200 Million of 8.875% Senior Notes due 2021 Nov 05 2014
BioScrip to Host Fourth Quarter and Year-end 2013 Earnings Call Nov 05 2014
BIOSCRIP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Nov 05 2014
BioScrip Reports Third Quarter 2014 Financial Results Nov 05 2014
Q3 2014 BioScrip Inc Earnings Release - After Market Close Nov 05 2014
Top three 'TINA' trades Oct 29 2014
Mario Gabelli Boosts BioScrip Inc. Position Oct 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK